SAGE Therapeutics Stock Price, News & Analysis (NASDAQ:SAGE)

$166.71 -1.77 (-1.05 %)
(As of 01/18/2018 04:00 PM ET)
Previous Close$166.71
Today's Range$166.13 - $172.97
52-Week Range$44.55 - $180.83
Volume500,749 shs
Average Volume1.06 million shs
Market Capitalization$6.84 billion
P/E Ratio-24.27
Dividend YieldN/A
Beta3.05

About SAGE Therapeutics (NASDAQ:SAGE)

SAGE Therapeutics logoSAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.

Receive SAGE News and Ratings via Email

Sign-up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:SAGE
CUSIPN/A
Phone+1-617-2998380

Debt

Debt-to-Equity RatioN/A
Current Ratio4.98%
Quick Ratio4.98%

Price-To-Earnings

Trailing P/E Ratio-24.2663755458515
Forward P/E Ratio-22.47
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$9.91 per share
Price / Book16.82

Profitability

Trailing EPS($6.87)
Net Income$-158,980,000.00
Net MarginsN/A
Return on Equity-89.46%
Return on Assets-78.94%

Miscellaneous

Employees135
Outstanding Shares41,050,000

SAGE Therapeutics (NASDAQ:SAGE) Frequently Asked Questions

What is SAGE Therapeutics' stock symbol?

SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

How were SAGE Therapeutics' earnings last quarter?

SAGE Therapeutics Inc (NASDAQ:SAGE) released its earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($1.97) EPS for the quarter, beating analysts' consensus estimates of ($1.98) by $0.01. The firm's revenue was up .0% on a year-over-year basis. View SAGE Therapeutics' Earnings History.

Where is SAGE Therapeutics' stock going? Where will SAGE Therapeutics' stock price be in 2018?

14 equities research analysts have issued 12-month price objectives for SAGE Therapeutics' stock. Their forecasts range from $86.00 to $280.00. On average, they expect SAGE Therapeutics' share price to reach $171.21 in the next year. View Analyst Ratings for SAGE Therapeutics.

What are Wall Street analysts saying about SAGE Therapeutics stock?

Here are some recent quotes from research analysts about SAGE Therapeutics stock:

  • 1. Needham & Company LLC analysts commented, "We hosted a call with expert Dr. Peter Kaplan to review the super refractory status epilepticus (SRSE) space and expectations for Sage Therapeutics’ drug IV brexanolone, which is currently being evaluated in the ongoing pivotal Phase 3 STATUS trial (results expected 3Q17). Dr. Kaplan has been practicing at Johns Hopkins for 30 years and his academic experience has been mostly clinical in nature. He is currently based at Johns Hopkins Bayview Medical Center and is consulted throughout the hospital for input regarding EEGs and for optimal management of status epilepticus. Below we highlight our key takeaways from the call." (6/13/2017)
  • 2. BMO Capital Markets analysts commented, "We spoke with two leading psychiatrists who agreed that these data, while early, look great; they were particularly impressed with the magnitude of effect, early onset, strong remission rate, and overall safety for SAGE-217 in MDD. This profile is considered the 'holy grail' in treating depression. The physicians were also very optimistic regarding the prospects for SAGE-217 in a placebo-controlled trial for MDD given the large effect size in the open-label (one said 75-80% chance of success)' We are now including risk-adjusted sales for SAGE-217 in MDD of $25mn in 2021 ramping up to $325mn in 2027. We partially offset that with some increased expenses; the net result was that our EPS changed by $(0.51)-4.04 in 2017-27, and our target goes to $82 from $68." (2/22/2017)
  • 3. Chardan Capital analysts commented, "Yesterday, Sage Therapeutics announced encouraging top-line phase II results from its open label clinical trial of orally-administered SAGE-217 for major depressive disorder (MDD). Our discussions yesterday with industry participants in the depression space suggested a decidedly positive view of the SAGE-217 data. We now note that the SAGE-217 result follows what to us, in our 12 July 2016 research, was "potentially clear, positive" phase II data for IV SAGE-547 in severe postpartum depression (PPD). Although our 20 July 2016 questions on SAGE-547 remain unanswered, we are reassured by the granting of Breakthrough Therapy Designation (BTD) for SAGE-547 by the FDA and PRIME Designation by EMA, which both likely independently considered the issues we raised. Our initial 24 May 2016 bearish view on Sage was based largely on our expectations of phase III data for SAGE-547 in super-refractory status epilepticus (SRSE), which were originally due to read out in 2H16. The timing of the data has since moved to 1H17, exposing any SAGE-547 SRSE bear thesis to the upside potential surrounding SAGE-217 in MDD, and more limited potential of SAGE-547 in PPD. Indeed, we now see upside risk elsewhere in Sage and thereby upgrade from Sell to Neutral, raising our PT from $18 to $60." (2/14/2017)
  • 4. Cowen Inc analysts commented, "Today SAGE announced positive top-line results from its Ph2 OL trial of SAGE-217 in." (2/13/2017)

Who are some of SAGE Therapeutics' key competitors?

Who are SAGE Therapeutics' key executives?

SAGE Therapeutics' management team includes the folowing people:

  • Kevin P. Starr, Independent Chairman of the Board (Age 54)
  • Jeffrey M. Jonas M.D., President, Chief Executive Officer, Director (Age 64)
  • Kimi E. Iguchi, Chief Financial Officer, Treasurer (Age 53)
  • Anne Marie Cook, Senior Vice President, General Counsel (Age 54)
  • Amy Schacterle Ph.D., Senior Vice President - Regulatory Affairs and Quality Assurance
  • Christopher Silber, Senior Vice President - Clinical Development
  • Albert J. Robichaud Ph.D., Chief Scientific Officer (Age 54)
  • Frank Sanders, Vice President of Sales and Marketing
  • Paul Hodgkins, Vice President - Health Economics and Outcomes Research and Value Demonstration
  • Thomas D. Anderson, Chief Commercial Strategy Officer (Age 60)

Who owns SAGE Therapeutics stock?

SAGE Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Schwab Charles Investment Management Inc. (0.46%) and Westpac Banking Corp (0.18%). Company insiders that own SAGE Therapeutics stock include Albert Robichaud, Jeffrey M Jonas, Kevin P Starr, Kimi Iguchi and Stephen Kanes. View Institutional Ownership Trends for SAGE Therapeutics.

Who bought SAGE Therapeutics stock? Who is buying SAGE Therapeutics stock?

SAGE Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc. and Westpac Banking Corp. View Insider Buying and Selling for SAGE Therapeutics.

How do I buy SAGE Therapeutics stock?

Shares of SAGE Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is SAGE Therapeutics' stock price today?

One share of SAGE Therapeutics stock can currently be purchased for approximately $166.71.

How big of a company is SAGE Therapeutics?

SAGE Therapeutics has a market capitalization of $6.84 billion. The biopharmaceutical company earns $-158,980,000.00 in net income (profit) each year or ($6.87) on an earnings per share basis. SAGE Therapeutics employs 135 workers across the globe.

How can I contact SAGE Therapeutics?

SAGE Therapeutics' mailing address is 215 1st St, CAMBRIDGE, MA 02142-1213, United States. The biopharmaceutical company can be reached via phone at +1-617-2998380 or via email at [email protected]


MarketBeat Community Rating for SAGE Therapeutics (SAGE)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  361 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  489
MarketBeat's community ratings are surveys of what our community members think about SAGE Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

SAGE Therapeutics (NASDAQ:SAGE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.792.792.932.91
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
11 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $171.21$171.21$86.79$85.82
Price Target Upside: 0.12% upside2.32% upside37.93% upside5.23% upside

SAGE Therapeutics (NASDAQ:SAGE) Consensus Price Target History

Price Target History for SAGE Therapeutics (NASDAQ:SAGE)

SAGE Therapeutics (NASDAQ:SAGE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/10/2018JPMorgan Chase & Co.Reiterated RatingBuyHighView Rating Details
12/11/2017CowenReiterated RatingBuyLowView Rating Details
12/8/2017Stifel NicolausReiterated RatingBuy$198.00LowView Rating Details
12/8/2017SunTrust BanksBoost Price TargetPositive$178.00HighView Rating Details
12/7/2017Raymond James FinancialReiterated RatingBuy$206.00HighView Rating Details
12/7/2017Canaccord GenuitySet Price TargetBuy -> Buy$140.00 -> $191.00HighView Rating Details
12/7/2017Needham & Company LLCBoost Price TargetBuy -> Buy$100.00 -> $193.00HighView Rating Details
12/7/2017Leerink SwannBoost Price Target$123.00 -> $246.00HighView Rating Details
12/7/2017BMO Capital MarketsReiterated RatingOutperform$203.00HighView Rating Details
12/7/2017Royal Bank of CanadaBoost Price TargetOutperform -> Sell$137.00 -> $280.00HighView Rating Details
11/16/2017Bank of AmericaLower Price TargetBuy$103.00 -> $101.00N/AView Rating Details
11/10/2017Chardan CapitalUpgradeNeutral -> Buy$60.00 -> $140.00N/AView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingBuy -> Buy$87.00N/AView Rating Details
8/4/2017HC WainwrightBoost Price TargetNeutral$86.00HighView Rating Details
7/15/2016William BlairReiterated RatingOutperform$75.00N/AView Rating Details
3/11/2016Lake Street CapitalInitiated CoverageBuy$90.00N/AView Rating Details
(Data available from 1/18/2016 forward)

Earnings

SAGE Therapeutics (NASDAQ:SAGE) Earnings History and Estimates Chart

Earnings by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

SAGE Therapeutics (NASDAQ SAGE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017($1.98)($1.97)ViewN/AView Earnings Details
8/3/2017Q2 2017($1.63)($1.88)ViewListenView Earnings Details
5/9/2017Q1 2017($1.61)($1.52)ViewListenView Earnings Details
2/23/2017Q4 2016($1.17)($1.50)ViewN/AView Earnings Details
11/3/2016Q316($1.10)($1.15)ViewN/AView Earnings Details
8/9/2016Q216($1.02)($1.08)ViewN/AView Earnings Details
5/5/2016Q1($0.98)($0.97)ViewListenView Earnings Details
2/24/2016Q4($0.94)($0.99)ViewListenView Earnings Details
11/5/2015Q3 2015($0.85)($0.84)ViewN/AView Earnings Details
8/12/2015Q215($0.68)($0.90)ViewN/AView Earnings Details
5/14/2015Q115($0.56)($0.66)ViewN/AView Earnings Details
2/27/2015Q414($0.44)($1.57)ViewN/AView Earnings Details
11/11/2014Q314($0.40)($0.50)ViewN/AView Earnings Details
8/14/2014Q214($1.23)($4.57)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

SAGE Therapeutics (NASDAQ:SAGE) Earnings Estimates

2018 EPS Consensus Estimate: ($7.37)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($1.79)($1.75)($1.77)
Q2 20182($1.87)($1.79)($1.83)
Q3 20182($1.91)($1.83)($1.87)
Q4 20182($1.95)($1.85)($1.90)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for SAGE Therapeutics (NASDAQ:SAGE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

SAGE Therapeutics (NASDAQ SAGE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 95.33%
Insider Trades by Quarter for SAGE Therapeutics (NASDAQ:SAGE)
Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

SAGE Therapeutics (NASDAQ SAGE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/10/2018Stephen KanesInsiderSell44,000$177.18$7,795,920.0046,348View SEC Filing  
12/21/2017Jeffrey M JonasCEOSell210,247$157.45$33,103,390.15211,473View SEC Filing  
12/14/2017Albert RobichaudInsiderSell60,000$159.43$9,565,800.00152,759View SEC Filing  
1/13/2017Kimi IguchiCFOSell10,000$53.92$539,200.00View SEC Filing  
11/17/2016Kimi IguchiCFOSell4,000$51.77$207,080.0075,739View SEC Filing  
11/11/2016Kimi IguchiCFOSell1,500$50.59$75,885.0079,739View SEC Filing  
9/7/2016Kimi IguchiCFOSell2,500$40.93$102,325.0081,239View SEC Filing  
7/12/2016Albert RobichaudInsiderSell22,000$40.00$880,000.00140,222View SEC Filing  
7/12/2016Kimi IguchiCFOSell5,000$49.55$247,750.0083,739View SEC Filing  
5/16/2016Kevin P StarrDirectorSell850,000$31.25$26,562,500.0065,227View SEC Filing  
4/19/2016Stephen KanesInsiderSell21,000$38.00$798,000.0025,948View SEC Filing  
1/25/2016Albert RobichaudInsiderSell20,000$40.02$800,400.00162,222View SEC Filing  
9/28/2015Stephen KanesinsiderSell6,000$46.42$278,520.0046,948View SEC Filing  
9/8/2015Kimi IguchiCFOSell3,000$54.84$164,520.0084,563View SEC Filing  
9/1/2015Steven M. PaulDirectorSell20,000$52.41$1,048,200.00683,650View SEC Filing  
8/31/2015Stephen KanesInsiderSell12,000$53.12$637,440.0031,948View SEC Filing  
7/23/2015Jeffrey M JonasInsiderSell3,000$76.79$230,370.00View SEC Filing  
7/6/2015Kimi IguchiCFOSell4,000$68.00$272,000.00View SEC Filing  
7/1/2015Albert RobichaudInsiderSell16,000$72.13$1,154,080.00View SEC Filing  
7/1/2015Steven M PaulDirectorSell20,000$69.40$1,388,000.00View SEC Filing  
6/24/2015Stephen KanesInsiderSell6,000$74.06$444,360.00View SEC Filing  
6/16/2015Jeffrey M JonasInsiderSell198,600$77.36$15,363,696.00View SEC Filing  
6/8/2015Thomas AndersonInsiderSell5,500$79.65$438,075.00View SEC Filing  
6/1/2015Albert RobichaudInsiderSell16,000$72.80$1,164,800.00View SEC Filing  
6/1/2015Steven M PaulDirectorSell20,000$72.34$1,446,800.00View SEC Filing  
2/25/2015Stephen KanesInsiderSell6,000$42.05$252,300.00View SEC Filing  
1/26/2015Stephen KanesInsiderSell6,000$37.29$223,740.00View SEC Filing  
7/23/2014James M FratesDirectorBuy5,000$18.00$90,000.00View SEC Filing  
7/23/2014Stephen KanesInsiderBuy3,000$18.00$54,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

SAGE Therapeutics (NASDAQ SAGE) News Headlines

Source:
DateHeadline
SAGE Therapeutics (SAGE) vs. aTyr Pharma (LIFE) Financial SurveySAGE Therapeutics (SAGE) vs. aTyr Pharma (LIFE) Financial Survey
www.americanbankingnews.com - January 16 at 1:10 AM
Stephen Kanes Sells 44,000 Shares of SAGE Therapeutics Inc (SAGE) StockStephen Kanes Sells 44,000 Shares of SAGE Therapeutics Inc (SAGE) Stock
www.americanbankingnews.com - January 12 at 6:26 PM
Bloomberg Markets: Sage Battling Depression, Powerful CultureBloomberg Markets: Sage Battling Depression, Powerful Culture
www.bloomberg.com - January 11 at 12:03 PM
SAGE Therapeutics (SAGE) Given "Buy" Rating at JPMorgan Chase & Co.SAGE Therapeutics (SAGE) Given "Buy" Rating at JPMorgan Chase & Co.
www.americanbankingnews.com - January 10 at 8:20 AM
Sage Therapeutics to Provide Pipeline Update at JP Morgan Healthcare Conference and Outline Key 2018 Initiatives to ... - Business Wire (press release)Sage Therapeutics to Provide Pipeline Update at JP Morgan Healthcare Conference and Outline Key 2018 Initiatives to ... - Business Wire (press release)
www.businesswire.com - January 8 at 3:41 PM
Sage Therapeutics to Provide Pipeline Update at J.P. Morgan Healthcare Conference and Outline Key 2018 Initiatives to Support Planned Evolution to a Fully-Integrated Commercial Biopharmaceutical CompanySage Therapeutics to Provide Pipeline Update at J.P. Morgan Healthcare Conference and Outline Key 2018 Initiatives to Support Planned Evolution to a Fully-Integrated Commercial Biopharmaceutical Company
finance.yahoo.com - January 8 at 8:26 AM
Sage Therapeutics to Present at JP Morgan Healthcare Conference on Tuesday, January 9, 2018 - Business Wire (press release)Sage Therapeutics to Present at JP Morgan Healthcare Conference on Tuesday, January 9, 2018 - Business Wire (press release)
www.businesswire.com - January 2 at 8:51 PM
Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018
finance.yahoo.com - January 2 at 8:51 PM
7 Notable Biotechs With Data Expected By Years End7 Notable Biotechs With Data Expected By Year's End
finance.yahoo.com - December 30 at 10:58 AM
Sage Therapeutics CEO cashes in $35M worth of stock optionsSage Therapeutics CEO cashes in $35M worth of stock options
finance.yahoo.com - December 28 at 3:10 PM
IWO, GRUB, SAGE, EPAM: ETF Outflow Alert - NasdaqIWO, GRUB, SAGE, EPAM: ETF Outflow Alert - Nasdaq
www.nasdaq.com - December 27 at 1:07 PM
SAGE Therapeutics Inc (SAGE) Given Average Rating of "Buy" by AnalystsSAGE Therapeutics Inc (SAGE) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - December 25 at 3:57 AM
Sage Therapeutics Inc (SAGE) President & CEO Jeffrey M Jonas Sold $35.1 million of SharesSage Therapeutics Inc (SAGE) President & CEO Jeffrey M Jonas Sold $35.1 million of Shares
finance.yahoo.com - December 22 at 9:23 PM
Jeffrey M. Jonas Sells 210,247 Shares of SAGE Therapeutics Inc (SAGE) StockJeffrey M. Jonas Sells 210,247 Shares of SAGE Therapeutics Inc (SAGE) Stock
www.americanbankingnews.com - December 22 at 5:38 PM
Zacks: Brokerages Anticipate Sage Therapeutics, Inc. (SAGE) Will Post Earnings of -$2.04 Per ShareZacks: Brokerages Anticipate Sage Therapeutics, Inc. (SAGE) Will Post Earnings of -$2.04 Per Share
www.americanbankingnews.com - December 17 at 5:30 AM
Sage Therapeutics, Inc. (SAGE) Insider Sells $9,565,800.00 in StockSage Therapeutics, Inc. (SAGE) Insider Sells $9,565,800.00 in Stock
www.americanbankingnews.com - December 14 at 8:50 PM
Why Biotech Sage Therapeutics May Keep SoaringWhy Biotech Sage Therapeutics May Keep Soaring
finance.yahoo.com - December 13 at 11:46 AM
Sage Therapeutics Reaches Analyst Target Price - NasdaqSage Therapeutics Reaches Analyst Target Price - Nasdaq
www.nasdaq.com - December 12 at 11:57 AM
Cowen Reiterates "Buy" Rating for Sage Therapeutics (SAGE)Cowen Reiterates "Buy" Rating for Sage Therapeutics (SAGE)
www.americanbankingnews.com - December 11 at 4:28 PM
Gene therapy stocks to watchGene therapy stocks to watch
finance.yahoo.com - December 9 at 11:23 AM
Sage CEO hopes experimental depression drug will be as big as ProzacSage CEO hopes experimental depression drug will be as big as Prozac
finance.yahoo.com - December 9 at 11:23 AM
Sage Therapeutics (SAGE) "Buy" Rating Reiterated at Stifel NicolausSage Therapeutics' (SAGE) "Buy" Rating Reiterated at Stifel Nicolaus
www.americanbankingnews.com - December 9 at 9:22 AM
Sage Therapeutics (SAGE) Stock Rating Reaffirmed by J P Morgan Chase & CoSage Therapeutics (SAGE) Stock Rating Reaffirmed by J P Morgan Chase & Co
www.americanbankingnews.com - December 8 at 10:28 PM
Sage Therapeutics (SAGE) Price Target Raised to $193.00 at Needham & Company LLCSage Therapeutics (SAGE) Price Target Raised to $193.00 at Needham & Company LLC
www.americanbankingnews.com - December 8 at 6:50 PM
Canaccord Genuity Reiterates "$191.00" Price Target for Sage Therapeutics (SAGE)Canaccord Genuity Reiterates "$191.00" Price Target for Sage Therapeutics (SAGE)
www.americanbankingnews.com - December 8 at 6:50 PM
Sage Therapeutics (SAGE) Given "Buy" Rating at Raymond James FinancialSage Therapeutics (SAGE) Given "Buy" Rating at Raymond James Financial
www.americanbankingnews.com - December 8 at 6:08 PM
Sage Therapeutics takes on major depressive disorderSage Therapeutics takes on major depressive disorder
finance.yahoo.com - December 8 at 3:35 PM
Sage CEO hopes for a Prozac moment with experimental depression drugSage CEO hopes for a Prozac moment with experimental depression drug
finance.yahoo.com - December 8 at 3:35 PM
BRIEF-Sage Therapeutics Reports Positive Results From Phase 2 Placebo-Controlled Trial Of Sage-217 In Major Depressive DisorderBRIEF-Sage Therapeutics Reports Positive Results From Phase 2 Placebo-Controlled Trial Of Sage-217 In Major Depressive Disorder
www.businessinsider.com - December 8 at 11:42 AM
SAGE Therapeutics Inc. (SAGE) Vaulted To A New High On Study ResultsSAGE Therapeutics Inc. (SAGE) Vaulted To A New High On Study Results
www.rttnews.com - December 8 at 11:42 AM
Sage Therapeutics to Present at BMO Prescriptions for Success Healthcare ConferenceSage Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference
finance.yahoo.com - December 8 at 11:42 AM
Sage Therapeutics shares gain another 2% as SunTrust raises stock price target to $178 vs. $116Sage Therapeutics shares gain another 2% as SunTrust raises stock price target to $178 vs. $116
finance.yahoo.com - December 8 at 11:42 AM
Why Marinus Pharmaceuticals Shares Spiked On Sage Therapeutics NewsWhy Marinus Pharmaceuticals Shares Spiked On Sage Therapeutics News
finance.yahoo.com - December 8 at 11:42 AM
Sage Therapeutics (SAGE) Given New $178.00 Price Target at SunTrust BanksSage Therapeutics (SAGE) Given New $178.00 Price Target at SunTrust Banks
www.americanbankingnews.com - December 8 at 10:02 AM
Sage Therapeutics (SAGE) Price Target Increased to $246.00 by Analysts at Leerink SwannSage Therapeutics (SAGE) Price Target Increased to $246.00 by Analysts at Leerink Swann
www.americanbankingnews.com - December 7 at 5:00 PM
Sage Therapeutics (SAGE) Price Target Raised to $280.00Sage Therapeutics (SAGE) Price Target Raised to $280.00
www.americanbankingnews.com - December 7 at 4:26 PM
BMO Capital Markets Reiterates Outperform Rating for Sage Therapeutics (SAGE)BMO Capital Markets Reiterates Outperform Rating for Sage Therapeutics (SAGE)
www.americanbankingnews.com - December 7 at 4:26 PM
Sage Therapeutics (SAGE) Price Target Increased to $225.00 by Analysts at Chardan CapitalSage Therapeutics (SAGE) Price Target Increased to $225.00 by Analysts at Chardan Capital
www.americanbankingnews.com - December 7 at 3:40 PM
Cowen Raises Sage Value On New Phase 2 Trial SuccessCowen Raises Sage Value On New Phase 2 Trial Success
www.msn.com - December 7 at 3:40 PM
Could Sage Therapeutics’ Depression Drug Be the Next Big Thing?Could Sage Therapeutics’ Depression Drug Be the Next Big Thing?
247wallst.com - December 7 at 3:40 PM
Sage Therapeutics stock rockets 73% on hopes for breakthrough depression drugSage Therapeutics stock rockets 73% on hopes for breakthrough depression drug
www.marketwatch.com - December 7 at 3:40 PM
Biotech Sage Therapeutics skyrockets more than 70 percent after depression drug breakthroughBiotech Sage Therapeutics skyrockets more than 70 percent after depression drug breakthrough
finance.yahoo.com - December 7 at 3:40 PM
Charting the Market: Sage Therapeutics Could Cure Your BluesCharting the Market: Sage Therapeutics Could Cure Your Blues
finance.yahoo.com - December 7 at 3:40 PM
Sage Therapeutics Rises 70% on Strong Phase 2 ResultsSage Therapeutics Rises 70% on Strong Phase 2 Results
finance.yahoo.com - December 7 at 3:40 PM
Sage shares surge as depression drug succeeds mid-stage trialSage shares surge as depression drug succeeds mid-stage trial
www.reuters.com - December 7 at 11:38 AM
Pre-Open Movers 12/07: (SAGE) (ENTL) (DPW) Higher; (LC) (EGLT) (VRNT) Lower (more...)Pre-Open Movers 12/07: (SAGE) (ENTL) (DPW) Higher; (LC) (EGLT) (VRNT) Lower (more...)
www.streetinsider.com - December 7 at 11:38 AM
SAGE Therapeutics Inc. (SAGE) Is Soaring To A New High On Study ResultsSAGE Therapeutics Inc. (SAGE) Is Soaring To A New High On Study Results
www.nasdaq.com - December 7 at 11:38 AM
Sage Therapeutics Reports Positive Top-line Results from Phase 2 Placebo-Controlled Trial of SAGE-217 in Major Depressive DisorderSage Therapeutics Reports Positive Top-line Results from Phase 2 Placebo-Controlled Trial of SAGE-217 in Major Depressive Disorder
finance.yahoo.com - December 7 at 11:38 AM
Sages depression drug succeeds in mid-stage study, shares soarSage's depression drug succeeds in mid-stage study, shares soar
finance.yahoo.com - December 7 at 11:38 AM
UPDATE: Sage Therapeutics shares soar more than 74% on positive trial of depression treatmentUPDATE: Sage Therapeutics shares soar more than 74% on positive trial of depression treatment
finance.yahoo.com - December 7 at 11:38 AM

SEC Filings

SAGE Therapeutics (NASDAQ:SAGE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

SAGE Therapeutics (NASDAQ:SAGE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

SAGE Therapeutics (NASDAQ SAGE) Stock Chart for Thursday, January, 18, 2018

Loading chart…

This page was last updated on 1/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.